165 related articles for article (PubMed ID: 31136823)
1. Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines.
Turrini F; Saliu F; Forlani G; Das AT; Van Lint C; Accolla RS; Berkhout B; Poli G; Vicenzi E
Virus Res; 2019 Aug; 269():197631. PubMed ID: 31136823
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the viral promoter.
Turrini F; Marelli S; Kajaste-Rudnitski A; Lusic M; Van Lint C; Das AT; Harwig A; Berkhout B; Vicenzi E
Retrovirology; 2015 Dec; 12():104. PubMed ID: 26683615
[TBL] [Abstract][Full Text] [Related]
3. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
4. The interferon-stimulated gene TRIM22: A double-edged sword in HIV-1 infection.
Vicenzi E; Poli G
Cytokine Growth Factor Rev; 2018 Apr; 40():40-47. PubMed ID: 29650252
[TBL] [Abstract][Full Text] [Related]
5. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
6. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
8. TRIM22 inhibits respiratory syncytial virus replication by targeting JAK-STAT1/2 signaling.
Wang Y; Chen Y; Lin Y; Quan Y; Xiao X; Zhang R
J Med Virol; 2021 Jun; 93(6):3412-3419. PubMed ID: 32803897
[TBL] [Abstract][Full Text] [Related]
9. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
10. Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization.
Graziano F; Aimola G; Forlani G; Turrini F; Accolla RS; Vicenzi E; Poli G
Sci Rep; 2018 Sep; 8(1):14249. PubMed ID: 30250078
[TBL] [Abstract][Full Text] [Related]
11. A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency.
Röling M; Mollapour Sisakht M; Ne E; Moulos P; Crespo R; Stoszko M; De Crignis E; Bodmer H; Kan TW; Akbarzadeh M; Harokopos V; Hatzis P; Palstra RJ; Mahmoudi T
mBio; 2021 Dec; 12(6):e0298021. PubMed ID: 34872356
[TBL] [Abstract][Full Text] [Related]
12. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.
Wightman F; Lu HK; Solomon AE; Saleh S; Harman AN; Cunningham AL; Gray L; Churchill M; Cameron PU; Dear AE; Lewin SR
AIDS; 2013 Nov; 27(18):2853-62. PubMed ID: 24189584
[TBL] [Abstract][Full Text] [Related]
13. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
14. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
15. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
16. Tripartite Motif 22 (TRIM22) protein restricts herpes simplex virus 1 by epigenetic silencing of viral immediate-early genes.
Reddi TS; Merkl PE; Lim SY; Letvin NL; Knipe DM
PLoS Pathog; 2021 Feb; 17(2):e1009281. PubMed ID: 33524065
[TBL] [Abstract][Full Text] [Related]
17. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
18. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
19. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
20. Jurkat-Derived (J-Lat, J1.1, and Jurkat E4) and CEM-Derived T Cell Lines (8E5 and ACH-2) as Models of Reversible Proviral Latency.
Rodari A; Poli G; Van Lint C
Methods Mol Biol; 2022; 2407():3-15. PubMed ID: 34985653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
